MYRIAD GENETICS INC business relationships
Companies named in MYRIAD GENETICS INC’s 10-K filed 2026-02-24, and public companies whose annual reports name MYRIAD GENETICS INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.6 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 0 / 100
- AI adoption
- 0 / 100
Named in MYRIAD GENETICS INC’s annual report 3
“There is no guarantee, however, that our efforts will be successful or that our GeneSight test will be covered by UnitedHealthcare or other payors in the future.” SEC filing
“• In September 2025, we announced a strategic collaboration with SOPHiA Genetics, Inc. to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.” SEC filing
“| Illumina, Inc. | | Non-exclusive license to certain rights held by or licensed to Illumina to intellectual property relating to non-invasive prenatal screening and the Prequel test. | | We pay Illumina a royalty based on the volume of Prequel testing administered by us. | |” SEC filing
Companies whose annual reports name MYRIAD GENETICS INC 1
“We are pursuing a partner-centric strategy and have key relationships with Tempus, Myriad Genetics, Inc., Moderna, and Merck, among others.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.